ライフサイエンスコーパス: kidney-pancreas transplantation

1 spital readmissions after kidney, liver, and kidney-pancreas transplantation.

2 ion is safe and effective after simultaneous kidney-pancreas transplantation.

3 hs, and 3 beyond 3 months after simultaneous kidney-pancreas transplantation.

4 ersus-host disease (GVHD) after simultaneous kidney-pancreas transplantation.

5 educing patient mortality after simultaneous kidney-pancreas transplantation.

6 Of the simultaneous pancreas and kidney, pancreas transplantation alone, and PAK transpla

7 RESULTS.: Simultaneous pancreas and kidney, pancreas transplantation alone, and pancreas aft

8 Kidney-pancreas transplantation alters the diabetic mili

9 ent successful pancreas transplantation (108 kidney/pancreas transplantation) and another 28 patients

10 including 18 HNF1B patients receiving SKT or kidney-pancreas transplantation, and in vitro experiment

11 e challenging in the setting of simultaneous kidney-pancreas transplantation, because a reduction in

12 gle kidney transplantation (SKT) or combined kidney-pancreas transplantation can be considered.

13 Combined kidney-pancreas transplantation (CKPT) with its associat

14 Sirolimus (SRL) rescue in kidney-pancreas transplantation has not been well descri

15 A1c 9.1%), nine IDDM patients after combined kidney-pancreas transplantation (HbA1c 5.8%), seven pati

16 ver, there are limited data on how kidney or kidney-pancreas transplantation influence continuous aut

17 Simultaneous kidney pancreas transplantation is a safe and effective

18 The aim of this study was to assess whether kidney-pancreas transplantation (KPT) compromises the pr

19 be at high risk and candidates for combined kidney-pancreas transplantation may be monitored more fr

20 arding the impact of preemptive simultaneous kidney-pancreas transplantation on recipient and graft o

21 cemia in patients with long-standing T1D via kidney-pancreas transplantation or in diabetic mice by t

22 sure decreased to 134/77 mm Hg 1 month after kidney/pancreas transplantation (P<0.001) and decreased

23 To assess the long-term outcome of kidney/pancreas transplantation, patients were identifie

24 We analyzed 30 simultaneous kidney-pancreas transplantations receiving tacrolimus, m

25 Successful kidney/pancreas transplantation results in a marked impr

26 pathy (BKVAN) in the setting of simultaneous kidney-pancreas transplantation (SKPT) has been inadequa

27 yzed 232 patients who underwent simultaneous kidney-pancreas transplantation (SPK) between 1993 and 1

28 tal 28 pancreas transplants (17 simultaneous kidney-pancreas transplantation [SPK], 5 pancreas after

29 idney transplantation (KTx) and simultaneous kidney-pancreas transplantation (SPKTx).

30 At 1 month after kidney/pancreas transplantation, the average number of a

31 st that, in patients undergoing simultaneous kidney/pancreas transplantation, the entity of dissynchr

32 unosuppressive agents may allow simultaneous kidney-pancreas transplantation to be performed without

33 current standard technique for simultaneous kidney pancreas transplantation usually involves transpl

34 The rate of first fracture after kidney-pancreas transplantation was 12.1% per patient ye

35 Dialysis at simultaneous kidney-pancreas transplantation was an independent signi

36 and renal failure who underwent simultaneous kidney-pancreas transplantation was found to have stage

37 ls for the first 3 months after simultaneous kidney-pancreas transplantation were 15-20 ng/ml.

38 1994 and December 1, 1998, 147 simultaneous kidney/pancreas transplantations were performed at our c

39 ewed all patients who underwent simultaneous kidney-pancreas transplantation with bladder drainage at

40 c autonomic function follows both kidney and kidney-pancreas transplantation with more pronounced imp

41 lost their pancreas graft after simultaneous kidney-pancreas transplantation with P-E drainage underw